{"id":2451,"date":"2022-02-15T11:44:32","date_gmt":"2022-02-15T11:44:32","guid":{"rendered":"https:\/\/touchmedicalmedia.com\/?p=2451"},"modified":"2022-02-23T11:29:51","modified_gmt":"2022-02-23T11:29:51","slug":"new-partnership-with-national-organization-for-rare-disorders-nord","status":"publish","type":"post","link":"https:\/\/touchmedicalmedia.com\/news\/new-partnership-with-national-organization-for-rare-disorders-nord\/","title":{"rendered":"New partnership with National Organization for Rare Disorders (NORD)"},"content":{"rendered":"
Touch Medical Media<\/span><\/a><\/span>\u00a0are delighted to announce a new partnership with National Organization for Rare Disorders (NORD)<\/p>\n NORD, is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with more than 300 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.<\/p>\n For more than 30 years, NORD has been providing services for patients and their families, rare disease patient organizations, medical professionals, and those seeking to develop new diagnostics and treatments. NORD are here to support every member of the rare disease community with services focused on one ultimate goal: to improve the lives of individuals and families affected by rare diseases. https:\/\/rarediseases.org\/<\/span> Wolfgang Linke, ESC 2021 \u2013 Key Pathomechanisms of TTNtv-dilated Cardiomyopathy<\/a><\/span><\/p>\n Current medical therapies available for craniopharyngiomas<\/a><\/span><\/p>\n Ferdy van Geest, ETA 2021: Efficacy of T3 analogue Triac for MCT8 deficiency<\/a><\/span><\/p>\n Dr Emanuel Della Torre on novel therapeutic approaches<\/a><\/span><\/p>\n Bob Geng, AAAAI 2021: Immunoglobulin Replacement Therapy<\/a><\/span><\/p>\n Listen to this interview with Prof. Tomas Jelinek on the unmet needs, prevention and treatment of Chikungunya virus<\/span><\/a><\/p>\n Bernd Schwahn – First-in-class treatment approach on Molybdenum cofactor deficiency (MoCD)<\/a><\/span><\/p>\n Renato Mantegazza – challenges that arise in treating myasthenia gravis<\/a><\/span><\/p>\n Bruton\u2019s Tyrosine Kinase Inhibitors for the Treatment of Waldenstr\u00f6m\u2019s Macroglobulinaemia: A Canadian Perspective<\/a><\/span><\/p>\n Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria<\/span><\/a><\/p>\n Paediatric Vernal Keratoconjunctivitis \u2013 The VEKTIS Study<\/a><\/span><\/p>\n
\n<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/h6>\n
touchCARDIO<\/strong><\/h6>\n
touchENDOCRINOLOGY<\/strong><\/h6>\n
touchIMMUNOLOGY<\/strong><\/h6>\n
touchINFECTIOUS DISEASES<\/strong><\/h6>\n
touchNEUROLOGY<\/strong><\/h6>\n
touchONCOLOGY<\/strong><\/h6>\n
touchOPHTHALMOLOGY<\/strong><\/h6>\n
touchRESPIRATORY<\/strong><\/h6>\n